XTalks

DECEMBER 19, 2023

In the fast-evolving pharmaceutical landscape, tracking the top-selling drugs offers valuable insights into trends, healthcare priorities and the dynamics of the global market. As we approach the end of 2023, a retrospective look at the statistics from 2022 reveals the top 20 drugs dominating retail sales. billion in sales in 2022.

Sales 64

Sales FDA Approval Drugs Vaccination 64

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

Pharma in Brief

AUGUST 9, 2021

On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. Health Canada is accepting comments on the Minister of Health’s proposal to amend the FDR and the Medical Devices Regulations until October 28, 2021.

Regulation 98

Regulation Drugs Manufacturing Production 98

XTalks

MAY 17, 2024

Given concerns about safety, the company said no unsafe products should be on the market, especially given that neither the FDA nor any global regulatory agency has reviewed the compounded products for safety, quality or efficacy. If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.

Sales 52

Sales FDA Approval Pharmacy Production 52

Pharma in Brief

MAY 4, 2023

The Ontario Superior Court ( ONSC ) has dismissed a claim for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations ) brought by Apotex Inc. Apotex ) for lost sales of its Apo-Atomoxetine product. Canadian Patent No. Apotex filed an ANDS for its generic Apo-Atomoxetine product.

Regulation 52

Regulation Sales Production Compliance 52

Pharma in Brief

FEBRUARY 8, 2024

On January 26, 2024, Health Canada published a Notice concerning its application of the definition of Canadian Reference Product ( CRP ) in the Food and Drug Regulations ( Regulations ). b) of the Regulations. b) of the Regulations.

Production 52

Production Generic Drugs Bioequivalency Drugs 52

Pharma in Brief

MAY 29, 2023

The CSP Guidance was revised to reflect amendments to the definition of “authorization for sale” in the Certificate of Supplementary Protection Regulations ( CSP Regulations ) and to reflect changes to Health Canada’s administrative practices. Certificate of Supplementary Protection Regulations , SOR/2017-165

Regulation 59

Regulation Sales Clinical Trials Clinical Trials 59

pharmaphorum

SEPTEMBER 15, 2020

As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. This is reinforced by web-focused marketing strategies that give them a highly-targeted approach when it comes to marketing execution.”. Be more agile .

Branding 114

Branding Marketing Pharma Companies Life Science 114

XTalks

AUGUST 3, 2023

While most post-marketing activities are typically oriented towards marketing, sales, and commercialization of the drug, pharmacovigilance is fundamentally patient-centric, focusing on the safety and efficacy of pharmaceutical products once they reach the market. How is this shift affecting your post-marketing work?

Regulation 97

Regulation Marketing Life Science Drugs 97

XTalks

APRIL 3, 2024

While Soliris had its market launch 17 years ago with $3.2 billion in sales in 2023, Ultomiris was approved in 2018 and generated $3 billion in revenue last year. Competitors in the PNH market include Novartis, which won approval for its factor B inhibitor Fabhalta (iptacopan), the first oral pill for PNH treatment, late last year.

FDA Approval 102

FDA Approval Sales Trials Development 102

Pharma in Brief

AUGUST 24, 2022

Importantly, the ONCA decision reaffirms that innovators are not liable beyond damages available under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations ) for the legitimate exercise of their rights under the Patent Act and the Regulations. Background. Eli Lilly Canada Inc.

Regulation 52

Regulation Compliance Life Science Sales 52

XTalks

MARCH 1, 2021

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? But if you thought the growing number of patients presenting with mask-associated dry eye would mean higher sales for Restasis, think again.

Sales 119

Sales Drugs Life Science Containment 119

Pharma Business Blog

MAY 10, 2021

Until 25th May 2021 all Medtech products that are admitted in Switzerland for the sale can be distributed also in the EU. Furthermore ,the new regulations define the implementation of a European centralised database by the regulatory authorities where all relevant data related to the sale of Medtech products have to be filed electronically.

Sales 52

Sales Production Life Science Regulation 52

Delveinsight

SEPTEMBER 8, 2021

Especially in the field of Pharmaceutical & Life Sciences, a company’s all-around product life-cycle stages, which consist of planning, designing, constructing, product testing, and commissioning processes are provided by a Pharma Consultant. Pharma Consultant. Pharma Consultancy Modus Operandi.

Marketing 52

Marketing Production Sales Life Science 52

pharmaphorum

SEPTEMBER 7, 2020

Wokingham, United Kingdom —4 September 2020 — PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Robert Bowdish as Director of Clinical Trials Sales for North America. Robert has wide-ranging healthcare industry sales experience.

Clinical Trials 52

Clinical Trials Clinical Trials Sales Compliance 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 97

Life Science Pharma Companies Sales Marketing 97

pharmaphorum

DECEMBER 15, 2022

of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. “The life sciences industry has the potential to be the wind in the sails of a UK innovation-led recovery, but in the face of this storm risks blowing us backwards. Returns have risen sharply from £0.6

Branding 72

Branding Life Science Manufacturing Medicine 72

Pharma in Brief

APRIL 13, 2021

The Food and Drug Regulations ( FDR ) have been amended to allow for continued expedited review of COVID-19 drugs (including vaccines) while transitioning to authorizations by way of a full notice of compliance ( NOC ) under the FDR. We reported on the IO and the government’s consultation regarding its transition plan last year.

Regulation 52

Regulation Drugs Vaccination Vaccine 52

Pharma in Brief

NOVEMBER 20, 2023

The Courts’ decisions provide insight into how natural health products are distinguished, under federal law, from cosmetics and from drugs subject to the Food and Drug Regulations. These distinctions are important as they determine the regulatory burden required to market a product in Canada.

Production 52

Production Cosmetics Regulation Branding 52

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. More potential patients equal more prescriptions which equals higher sales and bigger profits.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

pharmaphorum

NOVEMBER 23, 2022

Innovative offerings around market access. A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My I’ve always worked as a consultant for pricing and access strategies for clients, helping them to get drugs to market and access patients.

Life Science 98

Life Science Marketing Medicine Production 98

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. And the demand won’t be easing anytime soon.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JANUARY 26, 2023

BTK plays an important role in the immune system by regulating B cell receptor signaling through its effects on the development and maturation of B cells. This includes a greater focus on digital campaigns and diversifying marketing campaigns with race and ethnicity insights.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

pharmaphorum

JUNE 20, 2022

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation. Positive projections.

Drugs 52

Drugs Marketing Life Science Regulation 52

Pharma in Brief

JANUARY 19, 2023

Health Canada has launched a consultation on proposed amendments to the Food and Drug Regulations and Medical Devices Regulations (the Regulatory Amendments ). Consultation on the Regulatory Amendments, which have been published in the Canada Gazette, Part 1 , is open until March 27, 2023. We previously reported on the IO here.

Drugs 52

Drugs Regulation Clinical Trials Clinical Trials 52

XTalks

MAY 21, 2021

Drive marketing and branding efforts . As employees across an organization would need to be informed of health and safety regulations. . Sales and marketing departments are able to use webcasts as a measurable ROI when setting up product launches, video blogs or even web shows to drive awareness of products or services.

Marketing 116

Marketing Branding Production Sales 116

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. billion in pharmaceutical sales from 2021. billion, a 42.74

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharma in Brief

SEPTEMBER 22, 2020

On September 16, 2020, the Minister of Health signed an Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (the Interim Order ) which provides new regulatory pathways to expedite the approval of COVID-19 drugs and vaccines that have not yet been approved for sale in Canada.

Drugs 98

Drugs Vaccination Vaccine Regulation 98

pharmaphorum

OCTOBER 19, 2022

Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in life sciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the life sciences industry creates content.

Life Science 89

Life Science Compliance Production Pharma Companies 89

XTalks

JANUARY 25, 2023

TheracosBio will thus be going up against some major market competition. XTALKS WEBINAR: Review of Key Trends for Life Science Commercial Teams in 2023 Register for this free on-demand webinar to learn about the latest trends in sales and marketing campaigns that could help bolster commercial success for life science companies this year.

FDA Approval 52

FDA Approval Drugs Life Science Cosmetics 52

pharmaphorum

JANUARY 20, 2022

Companies seek efficiency and speed to market during the content creation process, review and approval cycles, and thus the collective time for content to be approved for distribution, says Ian Hale, vice president of commercial content at Veeva Systems. Every country has its regulations. Compliant pharma content.

Compliance 98

Compliance Branding Sales Marketing 98

Pharma in Brief

JANUARY 24, 2021

The Canadian pharma and life sciences space saw many developments in 2020, despite and in some cases because of the COVID-19 pandemic. The year saw the first trials and decisions in actions under the new Patented Medicines (Notice of Compliance) Regulations ( PM(NOC) Regulations ). Introduction.

Life Science 52

Life Science Regulation Medicine Drugs 52

XTalks

MARCH 28, 2024

In a statement announcing the approval and describing the mechanism of action of the drug, Merck said Winrevair improves the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH, reversing vascular and right ventricle remodeling. In 2023, sales of Uptravi hit $1.6 billion in 2032.

FDA Approval 81

FDA Approval Clinical Trials Clinical Trials Trials 81

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. Keytruda (Pembrolizumab) and Opdivo (Nivolumab).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Pharma Business Blog

JULY 27, 2021

With that, as of now Switzerland is considered as a ‘third country’ and Swiss MedTech companies lost their previously barrier-free access to the EU market and vice versa. Until 25 May 2021, all MedTech products that were admitted in Switzerland for sale could also be distributed in the EU and vice versa.

Compliance 52

Compliance Regulation Manufacturing Production 52